Bausch Health Stock Surges 40%: What's Next?

Bausch Health Companies (BHC) had a stellar July, with its stock surging nearly 40% on the back of two major catalysts. The first was a regulatory win in Canada: on July 6, the company announced that its schizophrenia drug Prokedi was added to the Quebec Health Insurance Board's formulary. This is a critical step for drug commercialization in Canada, as it follows federal approval and enables provincial coverage. Quebec is the first province to add Prokedi, marking a significant milestone for the drug's market access.

The second and more powerful catalyst came on July 27, when Bausch reported its second-quarter earnings. The company posted revenue of $2.85 billion, a 13% year-over-year increase, comfortably beating the consensus estimate of $2.66 billion. Adjusted net income soared 42% to $476 million, or $1.26 per share, also exceeding analyst expectations of $1.23 per share.

Digging into the segments, the Salix gastroenterology and hepatology business was a standout, with revenue jumping 21% to $758 million. The foundational eyecare unit, Bausch + Lomb, grew revenue by 9% to over $1.39 billion. Notably, all reporting units except one posted revenue growth, with that one remaining flat.

Management highlighted that this marked the thirteenth consecutive quarter of year-over-year growth in both revenue and adjusted EBITDA for operations excluding Bausch + Lomb. CEO Thomas Appio attributed this to "the strength of our portfolio, disciplined execution, and the dedication of our teams around the world."

Looking ahead, Bausch raised its full-year 2026 guidance for revenue to $10.79 billion to $11.04 billion, up from the previous range of $10.67 billion to $10.92 billion. Adjusted EBITDA guidance was also lifted to $4.05 billion to $4.18 billion, a significant increase from the prior $3.89 billion to $4.01 billion.

Bausch Health's impressive July performance underscores the strength of its diversified portfolio. The company operates across multiple therapeutic areas, including gastroenterology, eyecare, and neurology, which helps mitigate risks associated with any single drug or market. This diversification is clearly paying off, as evidenced by the consistent growth across its business units.

The regulatory win for Prokedi in Quebec is particularly significant. It not only opens the door to a new revenue stream in Canada but also sets a precedent for other provinces to follow. As Prokedi gains broader formulary coverage, it could become a meaningful growth driver for Bausch's neurology portfolio.

The earnings beat and raised guidance signal that management is confident in the company's trajectory. The 13 consecutive quarters of growth in revenue and adjusted EBITDA (excluding B+L) demonstrate operational discipline and effective execution. This consistency is a positive sign for investors looking for stable, long-term growth.

However, it's important to note that Bausch + Lomb, the eyecare unit, is a relative laggard compared to other segments. While it still grew revenue by 9%, its growth rate is slower than Salix's 21%. Investors should monitor whether B+L can accelerate its performance, as it remains a key part of the company's overall value proposition.

Looking ahead, Bausch's raised guidance for 2026 suggests that the company expects continued momentum. The increased adjusted EBITDA forecast, in particular, indicates improving profitability. This bodes well for future earnings and could support further stock price appreciation.